<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166897">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00925015</url>
  </required_header>
  <id_info>
    <org_study_id>0646-016</org_study_id>
    <secondary_id>2009_602</secondary_id>
    <nct_id>NCT00925015</nct_id>
  </id_info>
  <brief_title>Phase I Study of Dalotuzumab (MK0646) in Combination With Cetuximab and Irinotecan in Colorectal Cancer Patients (0646-016)</brief_title>
  <official_title>A Phase I Study of MK0646 in Combination With Cetuximab and Irinotecan in Patients With Advanced or Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purposes of this study are to assess the safety, tolerability, pharmacokinetic
      interactions and the Human Anti-Human Antibody of dalotuzumab in combination with cetuximab
      and irinotecan in patients with advanced or metastatic colorectal cancer in Japan.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Any clinical or laboratory adverse experiences</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic drug-drug interactions</measure>
    <time_frame>42 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human Anti-Human Antibody</measure>
    <time_frame>Until the 12 weeks after the last administration of MK0646</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dalotuzumab administered on Day 22 and 36</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dalotuzumab administered on Day 8, 22 and 36</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dalotuzumab administered on Day 1, 22 and 29</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dalotuzumab (MK0646)</intervention_name>
    <description>Arm 1: Dalotuzumab (10 mg/kg) intravenously administered on Day 22 and 36 Arm 2: Dalotuzumab (initial infusion 15 mg/kg, subsequent infusions 7.5 mg/kg) intravenous administered on Day 8, 22 and 36 Arm 3: Dalotuzumab (10 mg/kg) intravenously administered on Day 1, 22 and 29</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>dalotuzumab</other_name>
    <other_name>MK0646</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: cetuximab</intervention_name>
    <description>cetuximab (initial intravenous infusion 400 mg/m2, subsequent intravenous infusions 250 mg/m2, once weekly)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>cetuximab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: irinotecan</intervention_name>
    <description>irinotecan intravenous infusion (150 mg/m2, every other week) for 42 days</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>irinotecan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient Is 20 Years Of Age Or Older

          -  Patient Has A Histologically- Or Cytologically- Confirmed Colorectal Cancer

          -  Patient Has Previously Failed Both Irinotecan And Oxaliplatin Containing Regimens And
             Should Have Progressed On Or Within 3 Months Of Completing Their Last Line Of Therapy
             With Objective Radiological Evidence Of Progression As Verified By Previous
             Radiologic Scans

          -  Patient Must Have Adequate Organ Function

        Exclusion Criteria:

          -  Patient Has Had Chemotherapy, Radiotherapy, Or Biological Therapy Within 4 Weeks
             Prior To Initial Dosing On This Study Or Whose Toxicities From Agents Administrated 4
             Weeks Earlier Have Not Resolved To At Least Grade 1 Or Baseline

          -  Patient Has Experienced Intolerable Toxicity To Irinotecan Therapy

          -  Patient Has Prior Exposure To Igf-1r Inhibitors Or Egfr Inhibitors (E.G. Cetuximab)

          -  Patient Is Concurrently Using Growth Hormone (Gh), Or Growth Hormone Inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <results_reference>
    <citation>Doi T, Muro K, Yoshino T, Fuse N, Ura T, Takahari D, Feng HP, Shimamoto T, Noguchi K, Ohtsu A. Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2013 Sep;72(3):643-52. doi: 10.1007/s00280-013-2240-8.</citation>
    <PMID>23921573</PMID>
  </results_reference>
  <verification_date>January 2015</verification_date>
  <lastchanged_date>January 29, 2015</lastchanged_date>
  <firstreceived_date>June 17, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
